Zimmer Biomet Holdings, Inc. (ZBH)
USD 105.86
(-2.04%)
USD 105.86
(-2.04%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 5.99 Billion USD | 5.24% |
| 2022 | 5.69 Billion USD | -19.53% |
| 2021 | 7.07 Billion USD | -12.89% |
| 2020 | 8.12 Billion USD | -1.15% |
| 2019 | 8.22 Billion USD | -8.02% |
| 2018 | 8.93 Billion USD | -11.87% |
| 2017 | 10.14 Billion USD | -9.81% |
| 2016 | 11.24 Billion USD | -2.69% |
| 2015 | 11.55 Billion USD | 710.68% |
| 2014 | 1.42 Billion USD | -14.78% |
| 2013 | 1.67 Billion USD | -8.13% |
| 2012 | 1.82 Billion USD | 5.91% |
| 2011 | 1.71 Billion USD | 50.54% |
| 2010 | 1.14 Billion USD | 1.29% |
| 2009 | 1.12 Billion USD | 145.08% |
| 2008 | 460.1 Million USD | 341.13% |
| 2007 | 104.3 Million USD | 4.72% |
| 2006 | 99.6 Million USD | 22.06% |
| 2005 | 81.6 Million USD | -87.48% |
| 2004 | 651.5 Million USD | -41.26% |
| 2003 | 1.1 Billion USD | 607.79% |
| 2002 | 156.7 Million USD | -56.94% |
| 2001 | 363.9 Million USD | 0.0% |
| 2000 | - USD | 0.0% |
| 1999 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 5.79 Billion USD | -3.32% |
| 2024 Q3 | 6.57 Billion USD | 12.65% |
| 2024 Q2 | 5.83 Billion USD | 0.66% |
| 2023 FY | 5.99 Billion USD | 5.24% |
| 2023 Q1 | 5.78 Billion USD | 1.64% |
| 2023 Q2 | 5.7 Billion USD | -1.39% |
| 2023 Q3 | 5.48 Billion USD | -3.98% |
| 2023 Q4 | 5.99 Billion USD | 9.35% |
| 2022 Q4 | 5.69 Billion USD | -3.35% |
| 2022 Q1 | 6.3 Billion USD | -11.0% |
| 2022 Q2 | 6.15 Billion USD | -2.37% |
| 2022 Q3 | 5.89 Billion USD | -4.18% |
| 2022 FY | 5.69 Billion USD | -19.53% |
| 2021 Q3 | 7.51 Billion USD | -4.3% |
| 2021 Q1 | 7.83 Billion USD | -3.54% |
| 2021 Q2 | 7.85 Billion USD | 0.16% |
| 2021 FY | 7.07 Billion USD | -12.89% |
| 2021 Q4 | 7.07 Billion USD | -5.78% |
| 2020 Q4 | 8.12 Billion USD | -1.93% |
| 2020 Q1 | 9.66 Billion USD | 17.6% |
| 2020 FY | 8.12 Billion USD | -1.15% |
| 2020 Q2 | 8.2 Billion USD | -15.09% |
| 2020 Q3 | 8.28 Billion USD | 0.94% |
| 2019 FY | 8.22 Billion USD | -8.02% |
| 2019 Q2 | 8.71 Billion USD | -1.04% |
| 2019 Q3 | 8.33 Billion USD | -4.38% |
| 2019 Q4 | 8.22 Billion USD | -1.39% |
| 2019 Q1 | 8.81 Billion USD | -1.27% |
| 2018 Q3 | 9.19 Billion USD | -3.13% |
| 2018 Q4 | 8.92 Billion USD | -2.97% |
| 2018 FY | 8.93 Billion USD | -11.87% |
| 2018 Q2 | 9.49 Billion USD | -14.56% |
| 2018 Q1 | 11.11 Billion USD | 9.56% |
| 2017 Q3 | 10.42 Billion USD | -2.42% |
| 2017 Q2 | 10.68 Billion USD | -7.2% |
| 2017 Q1 | 11.51 Billion USD | 2.38% |
| 2017 FY | 10.14 Billion USD | -9.81% |
| 2017 Q4 | 10.14 Billion USD | -2.71% |
| 2016 Q3 | 11 Billion USD | 4.49% |
| 2016 Q1 | 11.11 Billion USD | -3.57% |
| 2016 Q4 | 11.24 Billion USD | 2.17% |
| 2016 FY | 11.24 Billion USD | -2.69% |
| 2016 Q2 | 10.53 Billion USD | -5.25% |
| 2015 Q3 | 11.91 Billion USD | -1.12% |
| 2015 Q2 | 12.04 Billion USD | 32.98% |
| 2015 Q1 | 9.06 Billion USD | 546.54% |
| 2015 FY | 11.55 Billion USD | 710.68% |
| 2015 Q4 | 11.52 Billion USD | -3.23% |
| 2014 Q1 | 1.68 Billion USD | 0.44% |
| 2014 Q4 | 1.4 Billion USD | -1.75% |
| 2014 Q2 | 1.68 Billion USD | 0.43% |
| 2014 FY | 1.42 Billion USD | -14.78% |
| 2014 Q3 | 1.42 Billion USD | -15.47% |
| 2013 Q1 | 1.7 Billion USD | -4.71% |
| 2013 FY | 1.67 Billion USD | -8.13% |
| 2013 Q4 | 1.67 Billion USD | -0.78% |
| 2013 Q3 | 1.68 Billion USD | -0.12% |
| 2013 Q2 | 1.68 Billion USD | -0.86% |
| 2012 Q2 | 2.4 Billion USD | -1.03% |
| 2012 Q1 | 2.43 Billion USD | 41.6% |
| 2012 FY | 1.82 Billion USD | 5.91% |
| 2012 Q4 | 1.78 Billion USD | -28.22% |
| 2012 Q3 | 2.48 Billion USD | 3.32% |
| 2011 Q2 | 1.14 Billion USD | 0.62% |
| 2011 Q3 | 1.54 Billion USD | 34.53% |
| 2011 Q4 | 1.71 Billion USD | 11.39% |
| 2011 FY | 1.71 Billion USD | 50.54% |
| 2011 Q1 | 1.14 Billion USD | -0.17% |
| 2010 Q4 | 1.14 Billion USD | 0.31% |
| 2010 Q2 | 1.13 Billion USD | 0.32% |
| 2010 FY | 1.14 Billion USD | 1.29% |
| 2010 Q1 | 1.12 Billion USD | -0.05% |
| 2010 Q3 | 1.13 Billion USD | 0.71% |
| 2009 FY | 1.12 Billion USD | 145.08% |
| 2009 Q4 | 1.12 Billion USD | 87.87% |
| 2009 Q3 | 600.2 Million USD | -8.16% |
| 2009 Q2 | 653.5 Million USD | -1.04% |
| 2009 Q1 | 660.4 Million USD | 43.53% |
| 2008 FY | 460.1 Million USD | 341.13% |
| 2008 Q1 | 116.9 Million USD | 12.08% |
| 2008 Q2 | 329.3 Million USD | 181.69% |
| 2008 Q3 | 331.1 Million USD | 0.55% |
| 2008 Q4 | 460.1 Million USD | 38.96% |
| 2007 Q1 | 100 Million USD | 0.4% |
| 2007 Q4 | 104.3 Million USD | 1.07% |
| 2007 Q3 | 103.2 Million USD | 8.4% |
| 2007 Q2 | 95.2 Million USD | -4.8% |
| 2007 FY | 104.3 Million USD | 4.72% |
| 2006 FY | 99.6 Million USD | 22.06% |
| 2006 Q1 | 81.5 Million USD | -0.12% |
| 2006 Q2 | 82.6 Million USD | 1.35% |
| 2006 Q3 | 100.9 Million USD | 22.15% |
| 2006 Q4 | 99.6 Million USD | -1.29% |
| 2005 Q1 | 426.3 Million USD | -34.57% |
| 2005 FY | 81.6 Million USD | -87.48% |
| 2005 Q2 | 268.1 Million USD | -37.11% |
| 2005 Q3 | 85.8 Million USD | -68.0% |
| 2005 Q4 | 81.6 Million USD | -4.9% |
| 2004 Q1 | 959.7 Million USD | -13.47% |
| 2004 Q4 | 651.5 Million USD | -4.25% |
| 2004 Q3 | 680.4 Million USD | -21.69% |
| 2004 Q2 | 868.9 Million USD | -9.46% |
| 2004 FY | 651.5 Million USD | -41.26% |
| 2003 FY | 1.1 Billion USD | 607.79% |
| 2003 Q1 | 76.9 Million USD | -50.93% |
| 2003 Q2 | 76 Million USD | -1.17% |
| 2003 Q3 | 80 Million USD | 5.26% |
| 2003 Q4 | 1.1 Billion USD | 1286.38% |
| 2002 Q3 | 248.9 Million USD | -20.43% |
| 2002 Q1 | 342.2 Million USD | -5.96% |
| 2002 Q2 | 312.8 Million USD | -8.59% |
| 2002 FY | 156.7 Million USD | -56.94% |
| 2002 Q4 | 156.7 Million USD | -37.04% |
| 2001 Q3 | 408.3 Million USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2001 FY | 363.9 Million USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2001 Q4 | 363.9 Million USD | -10.87% |
| 2000 Q4 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Abbott Laboratories | 15.87 Billion USD | 62.23% |
| Allurion Technologies Inc. | 41.85 Million USD | -14223.052% |
| Artivion, Inc. | 359.34 Million USD | -1568.387% |
| Avanos Medical, Inc. | 209.1 Million USD | -2767.145% |
| Butterfly Network, Inc. | 25.02 Million USD | -23854.929% |
| Butterfly Network, Inc. | 25.02 Million USD | -23854.929% |
| Bio-Rad Laboratories, Inc. | 1.4 Billion USD | -326.433% |
| Boston Scientific Corporation | 9.49 Billion USD | 36.839% |
| Perspective Therapeutics, Inc. | - USD | -Infinity% |
| CONMED Corporation | 991.25 Million USD | -504.81% |
| Edwards Lifesciences Corporation | 694.9 Million USD | -762.743% |
| Paragon 28, Inc. | 112.03 Million USD | -5251.424% |
| Glaukos Corporation | 383.73 Million USD | -1462.316% |
| Globus Medical, Inc. | 520.4 Million USD | -1052.028% |
| Inspire Medical Systems, Inc. | 24.84 Million USD | -24029.437% |
| Integer Holdings Corporation | 1.04 Billion USD | -475.932% |
| Medtronic plc | 26.04 Billion USD | 76.983% |
| Nevro Corp. | 221.82 Million USD | -2602.647% |
| Owlet, Inc. | 15.21 Million USD | -39300.631% |
| Penumbra, Inc. | 234.34 Million USD | -2458.301% |
| Vicarious Surgical Inc. | 14.83 Million USD | -40320.712% |
| Smith & Nephew plc | 3.08 Billion USD | -94.397% |
| Sonendo, Inc. | 40.35 Million USD | -14757.624% |
| STERIS plc | 3.38 Billion USD | -77.207% |
| Stryker Corporation | 12.99 Billion USD | 53.865% |
| Vapotherm, Inc. | 112.39 Million USD | -5234.187% |